GlassScriptPhysician profile
Alexa Hall
NPI 1366970287
$2,720.96
in general payments reported to CMS, 2019-2025
17 companies · $1,109 in 2025
The $1,109 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $413 · 2023: $599 · 2024: $599 · 2025: $1,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,300.45 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.11 | 2023-2025 | |
| Axsome Therapeutics, INC. | $496.63 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $438.34 | 2022-2023 | Spravato |
| Noven Therapeutics, LLC | $269.35 | 2024-2025 | Xelstrym |
| Supernus Pharmaceuticals, INC. | $257.13 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $234.31 | 2023-2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $131.20 | 2025 | Jornay Pm |
| Neos Therapeutics, LP | $80.84 | 2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Lundbeck LLC | $77.05 | 2025 | Rexulti |
| Tris Pharma INC | $47.35 | 2024 | Dyanavel Xr |
| Bausch Health US, LLC | $35.20 | 2022-2025 | Aplenzin |
| Tempus Ai, INC | $25.04 | 2024 | |
| Owp Pharmaceuticals, INC. | $24.75 | 2025 | Subvenite |
| Idorsia Pharmaceuticals US INC | $23.76 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $23.48 | 2023 | Ingrezza |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $22.77 | 2025 | Trintellix |
| Novo Nordisk INC | $19.65 | 2023 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.